Press Releases

September 20, 2017
Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Read More
September 14, 2017
/C O R R E C T I O N -- Protagonist Therapeutics, Inc./ Read More
September 11, 2017
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Read More
August 24, 2017
Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment Read More
August 8, 2017
Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights Read More
June 8, 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors Read More
May 30, 2017
Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease Read More
May 25, 2017
Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 Read More
May 24, 2017
Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity Read More
May 10, 2017
Protagonist Therapeutics Reports First Quarter 2017 Financial Results Read More
May 4, 2017
Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200 Read More
April 20, 2017
Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week Read More
March 9, 2017
Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference Read More
March 7, 2017
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results Read More
March 2, 2017
Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference Read More
February 17, 2017
Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohn's and Colitis Organization (ECCO) Congress Read More
February 1, 2017
Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference Read More
January 17, 2017
Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis Read More
January 5, 2017
Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100 Read More
November 14, 2016
Protagonist Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Read More